Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) EBT (2020 - 2023)

Historic EBT for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$21.0 million.

  • Terns Pharmaceuticals' EBT fell 3349.43% to -$21.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.0 million, marking a year-over-year decrease of 4946.53%. This contributed to the annual value of -$89.0 million for FY2024, which is 111.87% up from last year.
  • According to the latest figures from Q4 2023, Terns Pharmaceuticals' EBT is -$21.0 million, which was down 3349.43% from -$29.7 million recorded in Q3 2023.
  • Terns Pharmaceuticals' EBT's 5-year high stood at -$9.2 million during Q1 2020, with a 5-year trough of -$29.7 million in Q3 2023.
  • For the 4-year period, Terns Pharmaceuticals' EBT averaged around -$15.1 million, with its median value being -$13.8 million (2021).
  • As far as peak fluctuations go, Terns Pharmaceuticals' EBT tumbled by 283.75% in 2021, and later crashed by 7676.56% in 2023.
  • Quarter analysis of 4 years shows Terns Pharmaceuticals' EBT stood at -$10.4 million in 2020, then crashed by 33.64% to -$13.9 million in 2021, then dropped by 13.29% to -$15.7 million in 2022, then tumbled by 33.49% to -$21.0 million in 2023.
  • Its EBT was -$21.0 million in Q4 2023, compared to -$29.7 million in Q3 2023 and -$17.8 million in Q2 2023.